All In Biotech

Drug Trial Radar · NCT07070375

Pharmacokinetics and Safety of HRS-8427 in Healthy Volunteers and in Patients With Impaired Renal Function

A Multicenter, Parallel-Group, Open-Label Study of Pharmacokinetics and Safety of HRS-8427 Injection in Chinese Subjects With Renal Impairment

Last checked: Nov 20, 2026Latest source record: Jul 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

33

Actual

Start

Apr 19, 2023

Primary completion

Aug 23, 2023

Study completion Aug 23, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study evaluated the pharmacokinetic profile, safety, and tolerability of HRS-8427 injection in subjects with mild, moderate, severe, or end-stage renal disease (ESRD) requiring dialysis, using subjects with normal renal function as controls, to inform clinical dosing in patients with renal impairment.

Conditions

  • Gram-negative Bacterial Infections

Interventions

  • HRS-8427Drug

    HRS-8427

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: 4 days
  2. AUC0-tTime frame: 4 days
  3. AUC0-∞Time frame: 4 days
  4. TmaxTime frame: 4 days
  5. Ae: amount excreted. Urine samples will be collected.Time frame: 4 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.